Compare First Solar, Inc. (FSLR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Repligen Corporation Common Stock — how do they compare? First Solar, Inc. trades at $177.76 (market cap $20.05B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: First Solar, Inc. is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Repligen Corporation Common Stock for 0 Days on average.
| FSLR | RGEN | |
|---|---|---|
Market Cap | $20.05B | $11.14B |
Volume | 2,420,017 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $318.30 | $194.57 |
52-Week Low | $172.11 | $102.87 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $18.52B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $179.08, down 0.36% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins exceeding 29%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed estimates. Analyst consensus remains positive with a $268.82 price target, while technical indicators show resistance near $181 with oversold RSI conditions.
FSLR presents a value opportunity with attractive valuation multiples (P/E 11.5, P/S 3.73) and strong profitability (ROE 18.51%). Risks include sector-wide pressure from high borrowing costs, patent litigation uncertainties, and recent insider selling. The stock's 35% decline from peaks creates potential upside if solar sector sentiment improves.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
